aTyr Pharma, Inc. (ATYR)
3.82
+0.13
(+3.52%)
USD |
NASDAQ |
Nov 20, 16:00
3.80
-0.02
(-0.52%)
After-Hours: 20:00
aTyr Pharma Enterprise Value : -28.43M for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | -28.43M |
| November 19, 2026 | -28.75M |
| November 18, 2026 | -27.77M |
| November 17, 2026 | -25.49M |
| November 16, 2026 | -24.86M |
| November 13, 2026 | -22.69M |
| November 12, 2026 | -22.42M |
| November 11, 2026 | -21.02M |
| November 10, 2026 | -19.03M |
| November 09, 2026 | -18.98M |
| November 06, 2026 | -22.07M |
| November 05, 2026 | -22.88M |
| November 04, 2026 | -22.50M |
| November 03, 2026 | -21.37M |
| November 02, 2026 | -22.22M |
| October 30, 2026 | -25.61M |
| October 29, 2026 | -24.53M |
| October 28, 2026 | -25.12M |
| October 27, 2026 | -25.56M |
| October 26, 2026 | -22.61M |
| October 23, 2026 | -21.43M |
| October 22, 2026 | -20.94M |
| October 21, 2026 | -20.71M |
| October 20, 2026 | -20.61M |
| October 19, 2026 | -20.77M |
| Date | Value |
|---|---|
| October 16, 2026 | -20.54M |
| October 15, 2026 | -19.56M |
| October 14, 2026 | -19.61M |
| October 13, 2026 | -17.82M |
| October 12, 2026 | -16.44M |
| October 09, 2026 | -13.29M |
| October 08, 2026 | -12.37M |
| October 07, 2026 | -10.06M |
| October 06, 2026 | -9.549M |
| October 05, 2026 | -8.886M |
| October 02, 2026 | -9.168M |
| October 01, 2026 | -8.474M |
| September 30, 2026 | -7.580M |
| September 29, 2026 | -16.13M |
| September 28, 2026 | -17.11M |
| September 25, 2026 | -16.40M |
| September 24, 2026 | -13.20M |
| September 23, 2026 | -9.510M |
| September 22, 2026 | -11.35M |
| September 21, 2026 | -9.746M |
| September 18, 2026 | -10.71M |
| September 17, 2026 | -9.383M |
| September 16, 2026 | -8.637M |
| September 15, 2026 | -8.137M |
| September 14, 2026 | -8.196M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.052B |
| Alnylam Pharmaceuticals, Inc. | 18.66B |
| Anika Therapeutics, Inc. | 158.39M |
| Savara, Inc. | 776.30M |
| Arrowhead Pharmaceuticals, Inc. | 6.053B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -18.26M |
| Total Expenses (Quarterly) | 18.26M |
| EPS Diluted (Quarterly) | -7.433 |
| Earnings Yield | -569.1% |
| Normalized Earnings Yield | -569.09 |